Early Detection of Prostate Cancer Using PDL-1 and IL-6 In Najaf Al-Ashraf Governorate
DOI:
https://doi.org/10.46966/msjar.v6i4.352Keywords:
Safety PDL-1, Immunemarkers, and IL-6 ParametersAbstract
Background: Prostate cancer (PCa) stands as the most common type of cancer affecting men globally, exhibiting considerable differences in incidence and mortality rates across various populations. Aim the study: The study aims at the early diagnosis of prostate cancer using immunological markers. Methods: The current study, collected 240 samples blood divided into first group was a healthy which included man (60) while second group interested patients of prostate cancer from (180) man and by used ELAISA techniques for prognosis prostate cancer by serum parameters programmed cell death-ligand 1 (PDL-1and Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. Results: The statistical results of the immune markers (PDL-1, IL-6) when (180) samples collected from patients and (60) healthy showed relationship with cancer when compared with the results of healthy people. It was highly significant and p. Value <0.0011, in the Najaf Al-Ashraf. Conclusion: All immunological signs indicated the presence of cancer in the body, confirming the clinical signs approved by non-invasive diagnosis.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Qassim. M. Hashym, Sadeq Mohammad Jaafar Almosawi
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
